<unk>  (NRTIs and NtRTIs) began in the 1980s when the AIDS epidemic hit Western societies. NRTIs inhibit the<unk><unk>  (RT), an enzyme that controls the replication of the genetic material of the human immunodeficiency virus (HIV). The first NRTI was zidovudine, approved by the U.S. Food and Drug Administration (FDA) in 1987, which was the first step towards treatment of HIV. Six NRTI agents and one NtRTI have followed. The NRTIs and the NtRTI are analogues of endogenous 2´-deoxy-nucleoside and<unk> . Drug-resistant viruses are an inevitable consequence of prolonged exposure of HIV-1 to anti-HIV drugs.
Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors
Discovery and development of non-nucleoside reverse-transcriptase inhibitors
Zinc finger nuclease treatment of HIV
Innate resistance to HIV
Targeted covalent inhibitors
Viral strategies for immune response evasion
Vectors in gene therapy
Cancer vaccine targeting CD4+ T cells